Safety of Short Term Creatine Hydrochloride Dosing
Conditions
Brief summary
Background: Creatine monohydrate (typically 5-20 g/day) has a well-established safety profile across diverse populations. Creatine hydrochloride (CR-HCl) is a highly soluble creatine formulation that may allow effective supplementation at substantially lower doses (750 mg - 3 g/day); however, controlled human safety data specific to CR-HCl remain limited. Objective: To evaluate the short-term laboratory safety and tolerability of low-dose CR-HCl supplementation administered for 28 days in healthy adults.
Interventions
DIETARY_SUPPLEMENTcreatine supplementation
750 mg/day dosing
Sponsors
Vireo Systems, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* healthy adults
Exclusion criteria
* consumed creatine supplements in last 30 days significant medical conditions that could affect outcomes (e.g., diabetes)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| No adverse events | over 28 days |
Countries
United States
Outcome results
None listed